Authors
Loading...
Randomized trial demonstrates lower 180-day mortality alongside increased adverse events with a microaxial flow pump in STEMI cardiogenic shock, highlighting a critical efficacy-safety trade-off.
Møller et al. (2024) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: